Y Intercept Hong Kong Ltd Makes New $1.06 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)

Y Intercept Hong Kong Ltd bought a new stake in REGENXBIO Inc. (NASDAQ:RGNX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 137,402 shares of the biotechnology company’s stock, valued at approximately $1,062,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. GAMMA Investing LLC grew its stake in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC raised its stake in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the last quarter. Erste Asset Management GmbH purchased a new position in REGENXBIO in the third quarter valued at approximately $140,000. Finally, Intech Investment Management LLC purchased a new position in shares of REGENXBIO during the 3rd quarter valued at $161,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $6.67 on Thursday. The firm has a market capitalization of $330.47 million, a price-to-earnings ratio of -1.33 and a beta of 1.29. The stock has a fifty day moving average of $7.61 and a 200 day moving average of $9.50. REGENXBIO Inc. has a 52-week low of $6.44 and a 52-week high of $28.80.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on RGNX shares. Morgan Stanley restated an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Raymond James began coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.45.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.